The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration. PubMed: 21203549
1/200. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Use a concentration of 1 µg/ml.
Use a concentration of 1 µg/ml. Detects a band of approximately 50 kDa (predicted molecular weight: 50 kDa).
Non-specific receptor for endothelin 1, 2, and 3. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Expressed in placental stem villi vessels, but not in cultured placental villi smooth muscle cells.
Involvement in disease
Defects in EDNRB are a cause of Waardenburg syndrome type 4A (WS4A) [MIM:277580]; also known as Waardenburg-Shah syndrome. WS4A is characterized by the association of Waardenburg features (depigmentation and deafness) and the absence of enteric ganglia in the distal part of the intestine (Hirschsprung disease). Defects in EDNRB are the cause of Hirschsprung disease type 2 (HSCR2) [MIM:600155]; also known as aganglionic megacolon (MGC). HSCR2 is a congenital disorder characterized by absence of enteric ganglia along a variable length of the intestine. It is the most common cause of congenital intestinal obstruction. Early symptoms range from complete acute neonatal obstruction, characterized by vomiting, abdominal distention and failure to pass stool, to chronic constipation in the older child. Defects in EDNRB are the cause of ABCD syndrome (ABCDS) [MIM:600501]. ABCD syndrome is an autosomal recessive syndrome characterized by albinism, black lock at temporal occipital region, bilateral deafness, aganglionosis of the large intestine and total absence of neurocytes and nerve fibers in the small intestine.
Belongs to the G-protein coupled receptor 1 family. Endothelin receptor subfamily. EDNRB sub-subfamily.
Palmitoylation of Cys-402 was confirmed by the palmitoylation of Cys-402 in a deletion mutant lacking both Cys-403 and Cys-405.
Immunocytochemistry/ Immunofluorescence - Anti-Endothelin B Receptor antibody (ab39960)
ICC/IF image of ab39960 stained human HeLa cells. The cells were PFA fixed (10 min), permabilised in TBS-T (20 min) and incubated with the antibody (ab39960, 1µg/ml) for 1h at room temperature. 1%BSA / 10% normal serum / 0.3M glycine was used to quench autofluorescence and block non-specific protein-protein interactions. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red). DAPI was used to stain the cell nuclei (blue).
Western blot - Anti-Endothelin B Receptor antibody (ab39960)
All lanes : Anti-Endothelin B Receptor antibody (ab39960) at 1 µg/ml
Lane 1 : MCF7 (Human breast adenocarcinoma cell line) Whole Cell Lysate Lane 2 : MDA MB 361 (Human breast adenocarcinoma cell line) Whole Cell Lysate Lane 3 : SW480 (Human colon adenocarcinoma cell line) Whole Cell Lysate Lane 4 : LOVO (Human colon adenocarcinoma cell line) Whole Cell Lysate
Lysates/proteins at 20 µg per lane.
Secondary All lanes : Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Endothelin B Receptor antibody (ab39960)This image is courtesy of an Abreview submitted by Antibody Solutions
ab39960 staining human placenta sections in IHC-P. The tissue was fixed with formaldehyde and a heat mediated antigen retrival step was performed. Blocking of the sample was done with 5 minutes of peroxidase block and 10 minutes of protein block, followed by staining with ab39960 at 1/200 for 45 minutes at 20°C. A HRP conjugated goat anti-rabbit polyclonal antibody was used as the secondary antibody.
Cianfrocca R et al. Blocking endothelin-1-receptor/ß-catenin circuit sensitizes to chemotherapy in colorectal cancer. Cell Death Differ24:1811-1820 (2017).
Read more (PubMed: 28708138) »
Hall SM et al. Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment. Eur Respir J38:851-60 (2011).
Read more (PubMed: 21406517) »